Becton, Dickinson and Company $BDX Shares Sold by GW Henssler & Associates Ltd.

GW Henssler & Associates Ltd. reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 16.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,139 shares of the medical instruments supplier’s stock after selling 618 shares during the period. GW Henssler & Associates Ltd.’s holdings in Becton, Dickinson and Company were worth $719,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC raised its position in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in Becton, Dickinson and Company by 50.6% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier’s stock valued at $18,808,000 after acquiring an additional 27,581 shares during the last quarter. FORA Capital LLC acquired a new position in Becton, Dickinson and Company in the 1st quarter valued at $3,458,000. Foster Victor Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company in the 1st quarter valued at $6,406,000. Finally, GAMMA Investing LLC increased its holdings in Becton, Dickinson and Company by 29.9% in the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock valued at $744,000 after purchasing an additional 748 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Performance

BDX opened at $192.84 on Monday. The business’s 50 day moving average is $183.07 and its 200-day moving average is $193.83. The stock has a market cap of $55.27 billion, a PE ratio of 34.68, a price-to-earnings-growth ratio of 1.44 and a beta of 0.27. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.51 billion for the quarter, compared to analysts’ expectations of $5.50 billion. During the same quarter in the previous year, the company posted $3.50 earnings per share. The business’s revenue for the quarter was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 74.82%.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Claire Fraser sold 863 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $192.30, for a total transaction of $165,954.90. Following the completion of the transaction, the director owned 23,143 shares in the company, valued at $4,450,398.90. This trade represents a 3.59% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on BDX shares. Barclays lowered their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a report on Tuesday, June 3rd. Citigroup downgraded Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and decreased their price target for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. Morgan Stanley raised their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Piper Sandler reissued a “neutral” rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Four investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus target price of $211.44.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.